Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Short name Semaglutide

NCTNCT07043361 (opens ClinicalTrials.gov in a new tab)Other id0034-23-LEUOther idNon applicable
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
5,300 participants (actual)
Sponsor
Hillel Yaffe Medical Center · Other gov
Design
Not stated
Countries
1 country

Israel

Start
18 Dec 2023
Primary completion
21 Dec 2024
Completion
30 Apr 2025
First posted
29 Jun 2025
Last update posted
9 Jul 2025
Conditions
Metabolic Disease

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2023202420252026
  1. Ph –

    Semaglutide

    NCT07043361

    18 Dec 2023 to 30 Apr 2025

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Objective: Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction. Vitamin D has been implicated in metabolic regulation, yet its influence on semaglutide-induced outcomes remains unclear. Research Design and Methods: the investigators conducted a cross-sectional analysis of 5,300 adults with T2D, enrolled in Leumit Health Services, who initiated semaglutide therapy between February 1, 2019, and December 31, 2022. All patients had documented serum 25-hydroxyvitamin D \[25(OH)D\] levels prior to treatment initiation. Metabolic outcomes- including glycemic control (HbA1c), body mass index (BMI), and lipid profile- were assessed at 12 months. Associations between baseline 25(OH)D levels and metabolic changes were evaluated using multivariable regression models, adjusted for demographic and clinical covariates.

Interventions

  • semaglutideDrug

Arms1

  • Other

    diabetic patients on semaglutide

    we tested the relation between baseline vitamin D levels and metabolic amplification of semaglutide metabolic effects

Primary outcomes3

Outcomes the sponsor listed as primary.

  1. relative weight loss measured by BMI

    Time frame · 12 months from semaglutide initiation

    Registry description

    testing semaglutide induced weight loss as a function of baseline vitamin D levels

  2. glycemic control using Hgb1C

    Time frame · 12 months from semaglutide initiation

    Registry description

    testing semaglutide induced glycemic control as a function of baseline vitamin D levels

  3. lipid control using LDL and TG

    Time frame · 12 months from semaglutide initiation

    Registry description

    testing semaglutide induced lipid control as a function of baseline vitamin D levels

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies9

Studies that cite this trial.

Studies with results

3 studies on this page

Indexing hint: Clinical trial · 2022

5 results

Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.

Yabe et al. 2022Journal of diabetes investigationcited by 21

PMID 35174649PMC9248424DOI 10.1111/jdi.13773PUB-35174649

Free to read · publisher termsCC BY-NC5 results
Read at sourceSee results (5)

Indexing hint: Randomized controlled trial · 2021

10 results

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Wilding et al. 2021The New England journal of medicinecited by 3,862

PMID 33567185DOI 10.1056/nejmoa2032183PUB-33567185

Full text at the publisher10 results
Publisher pageSee results (10)

Indexing hint: Meta-analysis (pooled) · 2019

10 results

Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.

Kang et al. 2019Diabetes & metabolism journalcited by 30

PMID 30604598PMC6712219DOI 10.4093/dmj.2018.0070PUB-30604598

Free to read · publisher termsCC BY-NC10 results
Read at sourceSee results (10)

Indexing hint: Meta-analysis (pooled) · 2014

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis.

Kim et al. 2014Diabetes, obesity & metabolismcited by 141

PMID 24655583DOI 10.1111/dom.12293PUB-24655583

Full text at the publisher
Publisher page

More studies

5 studies on this page

PubMed tag: none · 2022

Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.

Evans et al. 2022Diabetes therapy : research, treatment and education of diabetes and related disorderscited by 5

PMID 35044569PMC8767360DOI 10.1007/s13300-021-01201-zPUB-35044569

Free to read · publisher termsCC BY-NC
Read at source

PubMed tag: none · 2022

Oral Semaglutide: Dosage in Special Situations.

Kalra et al. 2022Diabetes therapy : research, treatment and education of diabetes and related disorderscited by 2

PMID 35532859PMC9174361DOI 10.1007/s13300-022-01265-5PUB-35532859

Free to read · publisher termsCC BY-NC
Read at source

Indexing hint: Review · 2021

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.

Andersen et al. 2021Drugscited by 86

PMID 33964002PMC8217049DOI 10.1007/s40265-021-01499-wPUB-33964002

Free to read · publisher termsCC BY-NC
Read at source

Indexing hint: Review · 2018

Semaglutide for the Treatment of Type 2 Diabetes Mellitus.

Miles et al. 2018The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicianscited by 22

PMID 34861016PMC6231279DOI 10.1177/8755122518790925PUB-34861016

Rights unknown
Source link

Indexing hint: Animal study · 2014

Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion.

Yosida et al. 2014Diabetescited by 58

PMID 24824430DOI 10.2337/db13-1868PUB-24824430

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 80 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Diabetes type II treated with semaglutide * Available baseline vitamin D levels Exclusion Criteria: * Missing serum 25-hydroxyvitamin D (25\[OH\]D) data * Pregnant or lactating females

PepBank is a research reference. Talk to a doctor before you use any peptide.